| Variable | Total | Abatacept group | TNF inhibitor group | p-value |
|---|---|---|---|---|
| (n=892) | (n=252) | (n=640) | ||
| Age at initiation of first biologic (years), mean (SD) | 55.3 (13.5) | 52.2 (13.1) | 54.6 (13.7) | 0.018 |
| Women, n (%) | 705 (79.0) | 208 (82.5) | 497 (77.6) | 0.107 |
| Disease duration (years), mean (SD) | 8.7 (8.3) | 12.1 (8.15) | 7.3 (8.0) | <0.001 |
| Number of previous biological agents | ||||
| 0 | 605 (67.8) | 27 (10.7) | 578 (90.3) | <0.001 |
| 1 | 151 (13.6) | 71 (28.2) | 50 (7.8) | |
| ≥2 | 166 (18.6) | 154 (61.1) | 12 (1.9) | |
| Concomitant glucocorticoids (%) | 512 (57.4) | 134 (53.2) | 378 (59.1) | 0.109 |
| Rheumatoid factor (%) | 752 (84.3) | 214 (84.9) | 538 (84.1) | 0.751 |
| Basal DAS28 score, mean (SD) | ||||
| Clustered | 4.74 (1.63) | 4.86 (1.74) | 4.73 (1.63) | 0.597 |
| Number of previous bDMARD = 0 | n=667* | n=44* | n=623* | 0.495 |
| 4.70 (1.63) | 4.86 (1.74) | 4.69 (1.63) | ||
| Number of previous bDMARD = 1 | n=490* | n=71* | n=419* | <0.001 |
| 4.28 (1.93) | 5.20 (1.53) | 4.09 (1.95) | ||
| Number of previous bDMARD >2 | n=484* | n=137* | n=347* | 0.412 |
| 4.74 (4.17) | 4.99 (1.46) | 4.59 (5.17) | ||
*Number of treatments available to calculate DAS28 mean.